Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer

NCT00193453 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Gemcitabine
DRUG: Docetaxel
DRUG: Cetuximab

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]